Invention Grant
- Patent Title: Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
-
Application No.: US14611495Application Date: 2015-02-02
-
Publication No.: US09254313B2Publication Date: 2016-02-09
- Inventor: Hung V. Do
- Applicant: Amicus Therapeutics, Inc.
- Applicant Address: US NJ Cranbury
- Assignee: AMICUS THERAPEUTICS, INC.
- Current Assignee: AMICUS THERAPEUTICS, INC.
- Current Assignee Address: US NJ Cranbury
- Agency: Servilla Whitney LLC
- Main IPC: C07K1/00
- IPC: C07K1/00 ; C12N9/24 ; A61K38/00 ; A61K38/47
Abstract:
Described herein are variant, recombinant β-glucocerebrosidase proteins characterized as having increased stability relative to recombinant wild-type β-glucocerebrosidase. Also provided herein are variant, recombinant β-glucocerebrosidase proteins characterized as retaining more catalytic activity relative to recombinant wild-type β-glucocerebrosidase. Further described herein are variant, recombinant β-glucocerebrosidase proteins that can have amino acid variations at one or more of the following positions: 316, 317, 321 and 145. Methods of making the variant, recombinant β-glucocerebrosidase proteins are also described as well as methods of treating patients having lysosomal storage diseases.
Public/Granted literature
Information query
